Perspective Therapeutics, INC Schedule 13G passive stakes

Several entities affiliated with Millennium Management have filed a Schedule 13G, confirming their beneficial ownership of Perspective Therapeutics, Inc. common stock.

State Street Corporation has reported beneficial ownership of 5.3% of Perspective Therapeutics Inc.'s common stock as of June 30, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 5.3% of Perspective Therapeutics, Inc. common stock.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, reporting beneficial ownership of 4,893,883 shares, or 4.3%, of Perspective Therapeutics, Inc. common stock.

Morgan Stanley has filed a Schedule 13G, reporting a beneficial ownership of 2.6% in Perspective Therapeutics, Inc. as of March 31, 2026, indicating a reduction in its holdings.

Morgan Stanley has reported a 6.0% beneficial ownership stake in Perspective Therapeutics, Inc., holding 4,461,893 shares of common stock.

Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in Perspective Therapeutics, Inc., including shares from pre-funded warrants.

TCG Crossover Fund II, L.P., TCG Crossover Fund III, L.P., and their affiliates, along with Chen Yu, reported a combined beneficial ownership of 6.9% in Perspective Therapeutics, Inc. following a recent underwritten offering.

Qatar Investment Authority has disclosed a 6.2% beneficial ownership stake in Perspective Therapeutics Inc. through its subsidiary Q Healthcare Holding LLC.

FMR LLC and Abigail P. Johnson filed an amended Schedule 13G, reporting a 0.4% beneficial ownership in Perspective Therapeutics Inc. common stock.

FMR LLC and Abigail P. Johnson have reported an 8.2% beneficial ownership stake in Perspective Therapeutics Inc. common stock.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 0.0% in Perspective Therapeutics Inc. as of December 31, 2024.

Avidity Partners Management LP and affiliated entities, along with Michael Gregory, have disclosed a passive beneficial ownership of 4.2% in Perspective Therapeutics, Inc., holding 2,841,024 shares as of December 31, 2024.